MiR-206 as a biomarker for response to mesalamine treatment in ulcerative colitis

Carlos D. Minacapelli, Manisha Bajpai, Xin Geng, James Van Gurp, Elizabeth Poplin, Peter S. Amenta, Steven Brant, Kiron M. Das

Research output: Contribution to journalArticle

Abstract

Background MicroRNAs (miRNAs) are important post-translational regulators. Elevated levels of miR-206 in ulcerative colitis (UC) were associated with suppression of anti-inflammatory A3 adenosine receptor (A3AR) expression. However, the relationship of miR-206 to histologic remission in UC patients remains unknown. This study correlates expression levels of miR-206 with histologic remission in patients treated via long-term mesalamine treatment to identify a possible mode of action for this mainstay drug for UC. Methods Expression of miR-206 and its target A3AR were analyzed in HT29 cell line before and after mesalamine treatment (2 mM) at different time points (0, 4, 12, and 24 hours) by qRT-PCR and western blot analysis. Expression of miR-206 and pathological scores of colonoscopic biopsy specimens were studied in 10 UC patients treated with mesalamine treatment for 2 to 6 years. Results miR-206 transcripts decreased 2.23-fold (P = 0.0001) 4 hours after 2 mM mesalamine treatment in HT29 colon cells compared with untreated controls. However, the mRNA/protein levels of A3AR increased by 4-fold (P = 0.04) and 2-fold, respectively, in same cells. miR-206 relative expression decreased significantly in patients treated with 4.8 g of mesalamine (P = 0.002) but not with 2.4 g (P = 0.35). Tissue assessment of sequential mesalamine-treated colonoscopic biopsies indicate a strong correlation between downregulation of miR-206 and histologic improvement (R = 0.9111). Conclusion Mesalamine treatment has an effect on epithelial miRNAs. Downregulation of miR-206 by long-term mesalamine treatment may confer a protective effect in inducing and maintaining histologic remission. Thus, miR-206 expression levels can be utilized as a possible biomarker for therapeutic response to mesalamine treatment.

Original languageEnglish (US)
Pages (from-to)78-84
Number of pages7
JournalInflammatory bowel diseases
Volume25
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Mesalamine
Ulcerative Colitis
Biomarkers
Adenosine A3 Receptors
HT29 Cells
Therapeutics
MicroRNAs
Down-Regulation
Biopsy
Colon
Anti-Inflammatory Agents
Western Blotting
Cell Line
Polymerase Chain Reaction
Messenger RNA

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Gastroenterology

Keywords

  • mesalamine
  • microRNA
  • ulcerative colitis

Cite this

Minacapelli, Carlos D. ; Bajpai, Manisha ; Geng, Xin ; Van Gurp, James ; Poplin, Elizabeth ; Amenta, Peter S. ; Brant, Steven ; Das, Kiron M. / MiR-206 as a biomarker for response to mesalamine treatment in ulcerative colitis. In: Inflammatory bowel diseases. 2019 ; Vol. 25, No. 1. pp. 78-84.
@article{c2b808da8f944957891fd8786ef79f22,
title = "MiR-206 as a biomarker for response to mesalamine treatment in ulcerative colitis",
abstract = "Background MicroRNAs (miRNAs) are important post-translational regulators. Elevated levels of miR-206 in ulcerative colitis (UC) were associated with suppression of anti-inflammatory A3 adenosine receptor (A3AR) expression. However, the relationship of miR-206 to histologic remission in UC patients remains unknown. This study correlates expression levels of miR-206 with histologic remission in patients treated via long-term mesalamine treatment to identify a possible mode of action for this mainstay drug for UC. Methods Expression of miR-206 and its target A3AR were analyzed in HT29 cell line before and after mesalamine treatment (2 mM) at different time points (0, 4, 12, and 24 hours) by qRT-PCR and western blot analysis. Expression of miR-206 and pathological scores of colonoscopic biopsy specimens were studied in 10 UC patients treated with mesalamine treatment for 2 to 6 years. Results miR-206 transcripts decreased 2.23-fold (P = 0.0001) 4 hours after 2 mM mesalamine treatment in HT29 colon cells compared with untreated controls. However, the mRNA/protein levels of A3AR increased by 4-fold (P = 0.04) and 2-fold, respectively, in same cells. miR-206 relative expression decreased significantly in patients treated with 4.8 g of mesalamine (P = 0.002) but not with 2.4 g (P = 0.35). Tissue assessment of sequential mesalamine-treated colonoscopic biopsies indicate a strong correlation between downregulation of miR-206 and histologic improvement (R = 0.9111). Conclusion Mesalamine treatment has an effect on epithelial miRNAs. Downregulation of miR-206 by long-term mesalamine treatment may confer a protective effect in inducing and maintaining histologic remission. Thus, miR-206 expression levels can be utilized as a possible biomarker for therapeutic response to mesalamine treatment.",
keywords = "mesalamine, microRNA, ulcerative colitis",
author = "Minacapelli, {Carlos D.} and Manisha Bajpai and Xin Geng and {Van Gurp}, James and Elizabeth Poplin and Amenta, {Peter S.} and Steven Brant and Das, {Kiron M.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1093/ibd/izy279",
language = "English (US)",
volume = "25",
pages = "78--84",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

MiR-206 as a biomarker for response to mesalamine treatment in ulcerative colitis. / Minacapelli, Carlos D.; Bajpai, Manisha; Geng, Xin; Van Gurp, James; Poplin, Elizabeth; Amenta, Peter S.; Brant, Steven; Das, Kiron M.

In: Inflammatory bowel diseases, Vol. 25, No. 1, 01.01.2019, p. 78-84.

Research output: Contribution to journalArticle

TY - JOUR

T1 - MiR-206 as a biomarker for response to mesalamine treatment in ulcerative colitis

AU - Minacapelli, Carlos D.

AU - Bajpai, Manisha

AU - Geng, Xin

AU - Van Gurp, James

AU - Poplin, Elizabeth

AU - Amenta, Peter S.

AU - Brant, Steven

AU - Das, Kiron M.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background MicroRNAs (miRNAs) are important post-translational regulators. Elevated levels of miR-206 in ulcerative colitis (UC) were associated with suppression of anti-inflammatory A3 adenosine receptor (A3AR) expression. However, the relationship of miR-206 to histologic remission in UC patients remains unknown. This study correlates expression levels of miR-206 with histologic remission in patients treated via long-term mesalamine treatment to identify a possible mode of action for this mainstay drug for UC. Methods Expression of miR-206 and its target A3AR were analyzed in HT29 cell line before and after mesalamine treatment (2 mM) at different time points (0, 4, 12, and 24 hours) by qRT-PCR and western blot analysis. Expression of miR-206 and pathological scores of colonoscopic biopsy specimens were studied in 10 UC patients treated with mesalamine treatment for 2 to 6 years. Results miR-206 transcripts decreased 2.23-fold (P = 0.0001) 4 hours after 2 mM mesalamine treatment in HT29 colon cells compared with untreated controls. However, the mRNA/protein levels of A3AR increased by 4-fold (P = 0.04) and 2-fold, respectively, in same cells. miR-206 relative expression decreased significantly in patients treated with 4.8 g of mesalamine (P = 0.002) but not with 2.4 g (P = 0.35). Tissue assessment of sequential mesalamine-treated colonoscopic biopsies indicate a strong correlation between downregulation of miR-206 and histologic improvement (R = 0.9111). Conclusion Mesalamine treatment has an effect on epithelial miRNAs. Downregulation of miR-206 by long-term mesalamine treatment may confer a protective effect in inducing and maintaining histologic remission. Thus, miR-206 expression levels can be utilized as a possible biomarker for therapeutic response to mesalamine treatment.

AB - Background MicroRNAs (miRNAs) are important post-translational regulators. Elevated levels of miR-206 in ulcerative colitis (UC) were associated with suppression of anti-inflammatory A3 adenosine receptor (A3AR) expression. However, the relationship of miR-206 to histologic remission in UC patients remains unknown. This study correlates expression levels of miR-206 with histologic remission in patients treated via long-term mesalamine treatment to identify a possible mode of action for this mainstay drug for UC. Methods Expression of miR-206 and its target A3AR were analyzed in HT29 cell line before and after mesalamine treatment (2 mM) at different time points (0, 4, 12, and 24 hours) by qRT-PCR and western blot analysis. Expression of miR-206 and pathological scores of colonoscopic biopsy specimens were studied in 10 UC patients treated with mesalamine treatment for 2 to 6 years. Results miR-206 transcripts decreased 2.23-fold (P = 0.0001) 4 hours after 2 mM mesalamine treatment in HT29 colon cells compared with untreated controls. However, the mRNA/protein levels of A3AR increased by 4-fold (P = 0.04) and 2-fold, respectively, in same cells. miR-206 relative expression decreased significantly in patients treated with 4.8 g of mesalamine (P = 0.002) but not with 2.4 g (P = 0.35). Tissue assessment of sequential mesalamine-treated colonoscopic biopsies indicate a strong correlation between downregulation of miR-206 and histologic improvement (R = 0.9111). Conclusion Mesalamine treatment has an effect on epithelial miRNAs. Downregulation of miR-206 by long-term mesalamine treatment may confer a protective effect in inducing and maintaining histologic remission. Thus, miR-206 expression levels can be utilized as a possible biomarker for therapeutic response to mesalamine treatment.

KW - mesalamine

KW - microRNA

KW - ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=85058601369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058601369&partnerID=8YFLogxK

U2 - 10.1093/ibd/izy279

DO - 10.1093/ibd/izy279

M3 - Article

C2 - 30204869

AN - SCOPUS:85058601369

VL - 25

SP - 78

EP - 84

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 1

ER -